$TAK · TAKEDA PHARMACEUTICAL CO LTD SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for TAKEDA PHARMACEUTICAL CO LTD ($TAK) from October 29, 2026 through October 29, 2026, including 0 Form 10-K annual reports, 0 Form 10-Q quarterly earnings reports, 0 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$TAK 6-K — TAKEDA PHARMACEUTICAL CO LTD
The 172% net profit surge is largely non-operational (lower impairments, deferred tax benefits), while constant-currency core revenue actually contracted — a critical distinctio…
$TAK 6-K — TAKEDA PHARMACEUTICAL CO LTD
The stark gap between 171.6% reported profit growth and deteriorating constant-currency fundamentals — with CER guidance cut across all metrics — signals that Takeda's underlyin…